These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 20975714)

  • 1. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.
    Pethe K; Sequeira PC; Agarwalla S; Rhee K; Kuhen K; Phong WY; Patel V; Beer D; Walker JR; Duraiswamy J; Jiricek J; Keller TH; Chatterjee A; Tan MP; Ujjini M; Rao SP; Camacho L; Bifani P; Mak PA; Ma I; Barnes SW; Chen Z; Plouffe D; Thayalan P; Ng SH; Au M; Lee BH; Tan BH; Ravindran S; Nanjundappa M; Lin X; Goh A; Lakshminarayana SB; Shoen C; Cynamon M; Kreiswirth B; Dartois V; Peters EC; Glynne R; Brenner S; Dick T
    Nat Commun; 2010 Aug; 1(5):57. PubMed ID: 20975714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc
    Kalia NP; Shi Lee B; Ab Rahman NB; Moraski GC; Miller MJ; Pethe K
    Sci Rep; 2019 Jun; 9(1):8608. PubMed ID: 31197236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis.
    Machado D; Pires D; Perdigão J; Couto I; Portugal I; Martins M; Amaral L; Anes E; Viveiros M
    PLoS One; 2016; 11(2):e0149326. PubMed ID: 26919135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics.
    Machado D; Azzali E; Couto I; Costantino G; Pieroni M; Viveiros M
    Future Microbiol; 2018 Sep; 13():1383-1402. PubMed ID: 30259757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.
    O'Malley T; Alling T; Early JV; Wescott HA; Kumar A; Moraski GC; Miller MJ; Masquelin T; Hipskind PA; Parish T
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-
    Rehberg N; Omeje E; Ebada SS; van Geelen L; Liu Z; Sureechatchayan P; Kassack MU; Ioerger TR; Proksch P; Kalscheuer R
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
    Altaf M; Miller CH; Bellows DS; O'Toole R
    Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis.
    Rajput VS; Mehra R; Kumar S; Nargotra A; Singh PP; Khan IA
    Appl Microbiol Biotechnol; 2016 Jun; 100(12):5415-26. PubMed ID: 26887318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Energy Metabolism in
    Bald D; Villellas C; Lu P; Koul A
    mBio; 2017 Apr; 8(2):. PubMed ID: 28400527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.
    Blanco D; Perez-Herran E; Cacho M; Ballell L; Castro J; González Del Río R; Lavandera JL; Remuiñán MJ; Richards C; Rullas J; Vázquez-Muñiz MJ; Woldu E; Zapatero-González MC; Angulo-Barturen I; Mendoza A; Barros D
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1868-75. PubMed ID: 25583730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain.
    Jeon AB; Ackart DF; Li W; Jackson M; Melander RJ; Melander C; Abramovitch RB; Chicco AJ; Basaraba RJ; Obregón-Henao A
    Sci Rep; 2019 Feb; 9(1):1513. PubMed ID: 30728417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A piperidinol-containing molecule is active against
    Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
    J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
    [No Abstract]   [Full Text] [Related]  

  • 16. A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.
    Esposito M; Szadocka S; Degiacomi G; Orena BS; Mori G; Piano V; Boldrin F; Zemanová J; Huszár S; Barros D; Ekins S; Lelièvre J; Manganelli R; Mattevi A; Pasca MR; Riccardi G; Ballell L; Mikušová K; Chiarelli LR
    ACS Infect Dis; 2017 Jun; 3(6):428-437. PubMed ID: 28475832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
    Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaerobic Mycobacterium tuberculosis Cell Death Stems from Intracellular Acidification Mitigated by the DosR Regulon.
    Reichlen MJ; Leistikow RL; Scobey MS; Born SEM; Voskuil MI
    J Bacteriol; 2017 Dec; 199(23):. PubMed ID: 28874407
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
    Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
    Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ring-substituted imidazoles as a new class of anti-tuberculosis agents.
    Gupta P; Hameed S; Jain R
    Eur J Med Chem; 2004 Sep; 39(9):805-14. PubMed ID: 15337293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.